메뉴 건너뛰기




Volumn 16, Issue 5, 2010, Pages 516-521

Antipsychotic medication: The potential role of 5-HT1A receptor agonism

Author keywords

Antipsychotic; Schizophrenia; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; ACETYLCHOLINE; ALPHA [1 [2 (1,4 BENZODIOXAN 5 YLOXY)ETHYL] 3 PYRROLIDINYL] 4 FLUOROACETOPHENONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; BUSPIRONE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; EMONAPRIDE; F 15603; HALOPERIDOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; PEROSPIRONE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SSR 181507; TANDOSPIRONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

EID: 77949484291     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790361470     Document Type: Review
Times cited : (28)

References (90)
  • 1
    • 0029082109 scopus 로고
    • Symptoms, signs, and diagnosis of schizophrenia
    • Andreasen N. Symptoms, signs, and diagnosis of schizophrenia. Lancet 1995; 346: 477-81.
    • (1995) Lancet , vol.346 , pp. 477-481
    • Andreasen, N.1
  • 2
    • 0031967082 scopus 로고    scopus 로고
    • Suicide in schizophrenia: Risk factors and clozapine treatment
    • Meltzer H. Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry 1998; 59(Suppl 3): 15-20.
    • (1998) J Clin Psychiatry , vol.59 , Issue.SUPPL. 3 , pp. 15-20
    • Meltzer, H.1
  • 3
    • 0032868798 scopus 로고    scopus 로고
    • The role of serotonin in antipsychotic drug action
    • Meltzer H. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999; 21(2 Suppl): 106S-15S.
    • (1999) Neuropsychopharmacology , vol.21 , Issue.2 SUPPL.
    • Meltzer, H.1
  • 4
    • 33644875319 scopus 로고    scopus 로고
    • Occurrence and treatment of depressive comorbidity/ cosyndromality in schizophrenic psychoses: Conceptual and treatment issues
    • Möller H. Occurrence and treatment of depressive comorbidity/ cosyndromality in schizophrenic psychoses: conceptual and treatment issues. World J Biol Psychiatry 2005; 6: 247-63.
    • (2005) World J Biol Psychiatry , vol.6 , pp. 247-263
    • Möller, H.1
  • 5
    • 0033850147 scopus 로고    scopus 로고
    • Depression in Schizophrenia: Perspective in the Era of "Atypical" Antipsychotic Agents
    • Siris SG. Depression in Schizophrenia: Perspective in the Era of "Atypical" Antipsychotic Agents. Am J Psychiatry 2000; 157: 1379-89.
    • (2000) Am J Psychiatry , vol.157 , pp. 1379-1389
    • Siris, S.G.1
  • 8
    • 0017068246 scopus 로고
    • Antipsychotic drug doses and neuroleptic/dopamine receptors
    • Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-9.
    • (1976) Nature , vol.261 , pp. 717-719
    • Seeman, P.1    Lee, T.2    Chau-Wong, M.3    Wong, K.4
  • 9
    • 0034608741 scopus 로고    scopus 로고
    • Schizophrenia: More dopamine, more D2 receptors
    • Seeman P, Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci USA 2000; 97: 7673-5.
    • (2000) Proc Natl Acad Sci USA , vol.97 , pp. 7673-7675
    • Seeman, P.1    Kapur, S.2
  • 10
    • 0017585335 scopus 로고
    • Dopaminergic factors in human prolactin regulation: Effects of neuroleptics and dopamine
    • Langer G, Sachar E. Dopaminergic factors in human prolactin regulation: effects of neuroleptics and dopamine. Psychoneuroendocrinology 1977; 2: 373-8.
    • (1977) Psychoneuroendocrinology , vol.2 , pp. 373-378
    • Langer, G.1    Sachar, E.2
  • 11
    • 0037215345 scopus 로고    scopus 로고
    • Elevated prolactin levels in patients with schizophrenia: Mechanisms and related adverse effects
    • Halbreich U, Kinon B, Gilmore J, Kahn L. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003; 28(Suppl 1): 53-67.
    • (2003) Psychoneuroendocrinology , vol.28 , Issue.SUPPL. 1 , pp. 53-67
    • Halbreich, U.1    Kinon, B.2    Gilmore, J.3    Kahn, L.4
  • 12
    • 0037377202 scopus 로고    scopus 로고
    • Hyperprolactinemia in response to antipsychotic drugs: Characterization across comparative clinical trials
    • Kinon B, Gilmore J, Liu H, Halbreich U. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003; 28(Suppl 2): 69-82.
    • (2003) Psychoneuroendocrinology , vol.28 , Issue.SUPPL. 2 , pp. 69-82
    • Kinon, B.1    Gilmore, J.2    Liu, H.3    Halbreich, U.4
  • 13
    • 0033598803 scopus 로고    scopus 로고
    • Cognition, schizophrenia, and the atypical antipsychotic drugs
    • Meltzer HY, Park S, Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc Natl Acad Sci USA 1999; 96: 13591-3.
    • (1999) Proc Natl Acad Sci USA , vol.96 , pp. 13591-13593
    • Meltzer, H.Y.1    Park, S.2    Kessler, R.3
  • 15
    • 0028114486 scopus 로고
    • An overview of the mechanism of action of clozapine
    • Meltzer H. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994; 55(Suppl B): 47-52.
    • (1994) J Clin Psychiatry , vol.55 , Issue.SUPPL. B , pp. 47-52
    • Meltzer, H.1
  • 17
    • 0032734322 scopus 로고    scopus 로고
    • Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia
    • Kasper S, Hale A, Azorin J, Möller H. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999; 249(Suppl 2): 1-14.
    • (1999) Eur Arch Psychiatry Clin Neurosci , vol.249 , Issue.SUPPL. 2 , pp. 1-14
    • Kasper, S.1    Hale, A.2    Azorin, J.3    Möller, H.4
  • 18
    • 33645464191 scopus 로고    scopus 로고
    • Weight change with atypical antipsychotics in the treatment of schizophrenia
    • Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005; 19(Suppl 6): 16-27.
    • (2005) J Psychopharmacol , vol.19 , Issue.SUPPL. 6 , pp. 16-27
    • Haddad, P.1
  • 19
    • 33746846535 scopus 로고    scopus 로고
    • Differential metabolic effects of antipsychotic treatments
    • Haupt D. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 2006; 16(Suppl 3): S149-55.
    • (2006) Eur Neuropsychopharmacol , vol.16 , Issue.SUPPL. 3
    • Haupt, D.1
  • 20
    • 53449092050 scopus 로고    scopus 로고
    • Serotonergic approaches in the development of novel antipsychotics
    • Jones CA, McCreary AC. Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology 2008; 55: 1056-65.
    • (2008) Neuropharmacology , vol.55 , pp. 1056-1065
    • Jones, C.A.1    McCreary, A.C.2
  • 22
    • 22344431960 scopus 로고    scopus 로고
    • Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: Affinity, efficacy and potential implications for treatment of schizophrenia
    • Newman-Tancredi A, Assié ML, N., Ormière A, Danty N, Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 2005; 8: 341-56.
    • (2005) Int J Neuropsychopharmacol , vol.8 , pp. 341-356
    • Newman-Tancredi, A.1    Assié2    ML, N.3    Ormière, A.4    Danty, N.5    Cosi, C.6
  • 23
    • 33645451501 scopus 로고    scopus 로고
    • Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release
    • Cosi C, Carilla-Durand E, Assie MB, Ormiere AM, Maraval M, Leduc N, et al. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 2006; 535: 135-44.
    • (2006) Eur J Pharmacol , vol.535 , pp. 135-144
    • Cosi, C.1    Carilla-Durand, E.2    Assie, M.B.3    Ormiere, A.M.4    Maraval, M.5    Leduc, N.6
  • 24
    • 34247892865 scopus 로고    scopus 로고
    • F15063, a potential antipsychotic with D2//D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (I) in vitro receptor affinity and efficacy profile
    • Newman-Tancredi A, Assie MB, Martel JC, Cosi C, Slot LB, Palmier C, et al. F15063, a potential antipsychotic with D2//D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (I) in vitro receptor affinity and efficacy profile. Br J Pharmacol 2007; 151: 237-52.
    • (2007) Br J Pharmacol , vol.151 , pp. 237-252
    • Newman-Tancredi, A.1    Assie, M.B.2    Martel, J.C.3    Cosi, C.4    Slot, L.B.5    Palmier, C.6
  • 25
    • 0030063466 scopus 로고    scopus 로고
    • Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors
    • Newman-Tancredi A, Chaput C, Verriele L, Millan MJ. Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors. Neuropharmacology 1996; 35: 119-21.
    • (1996) Neuropharmacology , vol.35 , pp. 119-121
    • Newman-Tancredi, A.1    Chaput, C.2    Verriele, L.3    Millan, M.J.4
  • 26
    • 34347336444 scopus 로고    scopus 로고
    • Neuropharmacological profile of bifeprunox: Merits and limitations in comparison with other third-generation antipsychotics
    • Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 2007; 8: 539-54.
    • (2007) Curr Opin Investig Drugs , vol.8 , pp. 539-554
    • Newman-Tancredi, A.1    Cussac, D.2    Depoortere, R.3
  • 28
    • 0032466835 scopus 로고    scopus 로고
    • S 16924 ((R)-2-{1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)- ethyl]-pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol
    • Millan MJ, Schreiber R, Dekeyne A, Rivet J-M, Bervoets K, Mavridis M, et al. S 16924 ((R)-2-{1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)- ethyl]-pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 1998; 286: 1356-73.
    • (1998) J Pharmacol Exp Ther , vol.286 , pp. 1356-1373
    • Millan, M.J.1    Schreiber, R.2    Dekeyne, A.3    Rivet, J.-M.4    Bervoets, K.5    Mavridis, M.6
  • 29
    • 0026667827 scopus 로고
    • Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue
    • Mason S, Reynolds G. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur J Pharmacol 1992; 221: 397-8.
    • (1992) Eur J Pharmacol , vol.221 , pp. 397-398
    • Mason, S.1    Reynolds, G.2
  • 30
    • 0036089687 scopus 로고    scopus 로고
    • Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
    • Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-9.
    • (2002) J Pharmacol Exp Ther , vol.302 , pp. 381-389
    • Burris, K.D.1    Molski, T.F.2    Xu, C.3    Ryan, E.4    Tottori, K.5    Kikuchi, T.6
  • 31
    • 20344400385 scopus 로고    scopus 로고
    • Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic
    • Tadori Y, Miwa T, Tottori K, Burris K, Stark A, Mori T, et al. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 2005; 515: 10-9.
    • (2005) Eur J Pharmacol , vol.515 , pp. 10-19
    • Tadori, Y.1    Miwa, T.2    Tottori, K.3    Burris, K.4    Stark, A.5    Mori, T.6
  • 34
    • 0026098660 scopus 로고
    • Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia
    • Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 1991; 48: 355-63.
    • (1991) Life Sci , vol.48 , pp. 355-363
    • Hashimoto, T.1    Nishino, N.2    Nakai, H.3    Tanaka, C.4
  • 35
    • 0030273870 scopus 로고    scopus 로고
    • 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia
    • Burnet P, Eastwood S, Harrison P. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996; 15: 442-55.
    • (1996) Neuropsychopharmacology , vol.15 , pp. 442-455
    • Burnet, P.1    Eastwood, S.2    Harrison, P.3
  • 39
    • 0033696731 scopus 로고    scopus 로고
    • Improving the treatment of schizophrenia: Focus on serotonin (5-HT)1A receptors
    • Millan MJ. Improving the treatment of schizophrenia: Focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 2000; 295: 853-61.
    • (2000) J Pharmacol Exp Ther , vol.295 , pp. 853-861
    • Millan, M.J.1
  • 40
    • 0034745153 scopus 로고    scopus 로고
    • 1A receptor in schizophrenia: A promising target for novel atypical neuroleptics?
    • 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 2001; 15: 37-46.
    • (2001) J Psychopharmacol , vol.15 , pp. 37-46
    • Bantick, R.A.1    Deakin, J.F.W.2    Grasby, P.3
  • 43
    • 18544372627 scopus 로고    scopus 로고
    • Beyond hypofrontality: A quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia
    • Glahn D, Ragland J, Abramoff A, Barrett J, Laird A, Bearden C, et al. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum Brain Mapp 2005; 25: 60-9.
    • (2005) Hum Brain Mapp , vol.25 , pp. 60-69
    • Glahn, D.1    Ragland, J.2    Abramoff, A.3    Barrett, J.4    Laird, A.5    Bearden, C.6
  • 44
    • 77956751404 scopus 로고    scopus 로고
    • The cortical dopamine system: Role in memory and cognition
    • Goldman-Rakic P. The cortical dopamine system: role in memory and cognition. Adv Pharmacol 1998; 42: 707-11.
    • (1998) Adv Pharmacol , vol.42 , pp. 707-711
    • Goldman-Rakic, P.1
  • 45
    • 0029149615 scopus 로고
    • Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: A search for common ground
    • Weinberger D, Lipska B. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 1995; 16: 87-110.
    • (1995) Schizophr Res , vol.16 , pp. 87-110
    • Weinberger, D.1    Lipska, B.2
  • 46
    • 0037036059 scopus 로고    scopus 로고
    • 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex
    • Ichikawa J, Dai J, Meltzer H. 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res 2002; 939: 34-42.
    • (2002) Brain Res , vol.939 , pp. 34-42
    • Ichikawa, J.1    Dai, J.2    Meltzer, H.3
  • 47
    • 0036176263 scopus 로고    scopus 로고
    • Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum
    • Ichikawa J, Dai J, O'Laughlin I, Fowler W, Meltzer H. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002; 26: 325-39.
    • (2002) Neuropsychopharmacology , vol.26 , pp. 325-339
    • Ichikawa, J.1    Dai, J.2    O'Laughlin, I.3    Fowler, W.4    Meltzer, H.5
  • 49
    • 2942551105 scopus 로고    scopus 로고
    • Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain
    • Li Z, Ichikawa J, Dai J, Meltzer H. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004; 493: 75-83.
    • (2004) Eur J Pharmacol , vol.493 , pp. 75-83
    • Li, Z.1    Ichikawa, J.2    Dai, J.3    Meltzer, H.4
  • 50
    • 0027183471 scopus 로고
    • The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux
    • Pehek E, Meltzer H, Yamamoto B. The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. Eur J Pharmacol 1993; 240: 107-9.
    • (1993) Eur J Pharmacol , vol.240 , pp. 107-109
    • Pehek, E.1    Meltzer, H.2    Yamamoto, B.3
  • 51
    • 0028242723 scopus 로고
    • Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex
    • Nomikos G, Iurlo M, Andersson J, Kimura K, Svensson T. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berl) 1994; 115: 147-56.
    • (1994) Psychopharmacology (Berl) , vol.115 , pp. 147-156
    • Nomikos, G.1    Iurlo, M.2    Andersson, J.3    Kimura, K.4    Svensson, T.5
  • 52
    • 0030694503 scopus 로고    scopus 로고
    • Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation
    • Rollema H, Lu Y, Schmidt A, Zorn S. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 1997; 338: R3-5.
    • (1997) Eur J Pharmacol , vol.338
    • Rollema, H.1    Lu, Y.2    Schmidt, A.3    Zorn, S.4
  • 56
    • 0029787944 scopus 로고    scopus 로고
    • Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
    • Laruelle M, Abi-Dargham A, van Dyc CH, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235-40.
    • (1996) Proc Natl Acad Sci USA , vol.93 , pp. 9235-9240
    • Laruelle, M.1    Abi-Dargham, A.2    van Dyc, C.H.3    Gil, R.4    D'Souza, C.D.5    Erdos, J.6
  • 57
    • 0024247522 scopus 로고
    • The current staus of the the dopamine hypothesis of schizophrenia
    • Carlsson A. The current staus of the the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 179-86.
    • (1988) Neuropsychopharmacology , vol.1 , pp. 179-186
    • Carlsson, A.1
  • 59
    • 33645419546 scopus 로고    scopus 로고
    • The acute and chronic administration of (±)-8-hydroxy-2-(di-n-propylamino) tetralin significantly alters the activity of spontaneously active midbrain dopamine neurons in rats: An in vivo electrophysiological study
    • Nakamura K, Suzuki K, McCreary A, Ashby CJ. The acute and chronic administration of (±)-8-hydroxy-2-(di-n-propylamino) tetralin significantly alters the activity of spontaneously active midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse 2006; 59: 359-67.
    • (2006) Synapse , vol.59 , pp. 359-367
    • Nakamura, K.1    Suzuki, K.2    McCreary, A.3    Ashby, C.J.4
  • 60
    • 0031815815 scopus 로고    scopus 로고
    • Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535
    • Lejeune F, Millan MJ. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse 1998; 30: 172-80.
    • (1998) Synapse , vol.30 , pp. 172-180
    • Lejeune, F.1    Millan, M.J.2
  • 61
    • 0027336182 scopus 로고
    • The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons
    • Arborelius L, Chergui K, Murase S, Nomikos G, Höök B, Chouvet G, et al. The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn-Schmiedebergs Arch Pharmacol 1993; 347: 353-62.
    • (1993) Naunyn-Schmiedebergs Arch Pharmacol , vol.347 , pp. 353-362
    • Arborelius, L.1    Chergui, K.2    Murase, S.3    Nomikos, G.4    Höök, B.5    Chouvet, G.6
  • 62
    • 4544371130 scopus 로고    scopus 로고
    • Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex
    • Santana N, Bortolozzi A, Serrats J, Mengod G, Artigas F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 2004; 14: 1100-9.
    • (2004) Cereb Cortex , vol.14 , pp. 1100-1109
    • Santana, N.1    Bortolozzi, A.2    Serrats, J.3    Mengod, G.4    Artigas, F.5
  • 63
    • 0034810016 scopus 로고    scopus 로고
    • Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment
    • Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 2001; 158: 1722-5.
    • (2001) Am J Psychiatry , vol.158 , pp. 1722-1725
    • Sumiyoshi, T.1    Matsui, M.2    Nohara, S.3    Yamashita, I.4    Kurachi, M.5    Sumiyoshi, C.6
  • 64
    • 0035873389 scopus 로고    scopus 로고
    • The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia
    • Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, et al. The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Biol Psychiatry 2001; 49: 861-8.
    • (2001) Biol Psychiatry , vol.49 , pp. 861-868
    • Sumiyoshi, T.1    Matsui, M.2    Yamashita, I.3    Nohara, S.4    Kurachi, M.5    Uehara, T.6
  • 65
    • 0034030291 scopus 로고    scopus 로고
    • Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia
    • Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M, et al. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol 2000; 20: 386-8.
    • (2000) J Clin Psychopharmacol , vol.20 , pp. 386-388
    • Sumiyoshi, T.1    Matsui, M.2    Yamashita, I.3    Nohara, S.4    Uehara, T.5    Kurachi, M.6
  • 66
    • 34548189417 scopus 로고    scopus 로고
    • Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study
    • Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer H. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophr Res 2007; 95: 158-68.
    • (2007) Schizophr Res , vol.95 , pp. 158-168
    • Sumiyoshi, T.1    Park, S.2    Jayathilake, K.3    Roy, A.4    Ertugrul, A.5    Meltzer, H.6
  • 68
  • 72
  • 74
    • 0037498629 scopus 로고    scopus 로고
    • Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats
    • Winstanley C, Chudasama Y, Dalley J, Theobald D, Glennon J, Robbins T. Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology (Berl) 2003; 167: 304-14.
    • (2003) Psychopharmacology (Berl) , vol.167 , pp. 304-314
    • Winstanley, C.1    Chudasama, Y.2    Dalley, J.3    Theobald, D.4    Glennon, J.5    Robbins, T.6
  • 78
    • 21644447088 scopus 로고    scopus 로고
    • Novel antipsychotic agents with 5-HT(1A) agonist properties: Role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats
    • Kleven M, Barret-Grévoz C, Bruins Slot L, Newman-Tancredi A. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 2005; 49: 135-43.
    • (2005) Neuropharmacology , vol.49 , pp. 135-143
    • Kleven, M.1    Barret-Grévoz, C.2    Bruins Slot, L.3    Newman-Tancredi, A.4
  • 79
    • 34250166183 scopus 로고    scopus 로고
    • Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats
    • Auclair A, Galinier A, Besnard J, Newman-Tancredi A, Depoortère R. Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. Psychopharmacology 2007; 193: 45-54.
    • (2007) Psychopharmacology , vol.193 , pp. 45-54
    • Auclair, A.1    Galinier, A.2    Besnard, J.3    Newman-Tancredi, A.4    Depoortère, R.5
  • 82
    • 0342288642 scopus 로고    scopus 로고
    • The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia
    • Keck PJ, Strakowski S, McElroy S. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 2000; 61(Suppl 3): 4-9.
    • (2000) J Clin Psychiatry , vol.61 , Issue.SUPPL. 3 , pp. 4-9
    • Keck, P.J.1    Strakowski, S.2    McElroy, S.3
  • 83
    • 0037304917 scopus 로고    scopus 로고
    • 1A agonists in the treatment of depression?
    • 1A agonists in the treatment of depression? Biol Psychiatry 2003; 53: 193-203.
    • (2003) Biol Psychiatry , vol.53 , pp. 193-203
    • Blier, P.1    Ward, N.M.2
  • 84
    • 0027277135 scopus 로고
    • 1A receptor ligands in animal models of anxiety, impulsivity and depression: Multiple mechanisms of action?
    • 1A receptor ligands in animal models of anxiety, impulsivity and depression: Multiple mechanisms of action? Progr Neuro-Psychopharmacol Biol Psychiatry 1993; 17: 87-104.
    • (1993) Progr Neuro-Psychopharmacol Biol Psychiatry , vol.17 , pp. 87-104
    • Schreiber, R.1    De Vry, J.2
  • 85
  • 86
    • 0027275084 scopus 로고
    • Depression, demoralization and control over psychotic illness: A comparison of depressed and non-depressed patients with a chronic psychosis
    • Birchwood M, Mason R, MacMillan F, Healy J. Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med 1993; 23: 387-95.
    • (1993) Psychol Med , vol.23 , pp. 387-395
    • Birchwood, M.1    Mason, R.2    MacMillan, F.3    Healy, J.4
  • 88
    • 47349107934 scopus 로고    scopus 로고
    • Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: New concepts in treatment
    • Gur A, Oktayoglu P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment. Curr Pharm Des 2008; 14(13): 1274-94.
    • (2008) Curr Pharm Des , vol.14 , Issue.13 , pp. 1274-1294
    • Gur, A.1    Oktayoglu, P.2
  • 89
    • 47349097789 scopus 로고    scopus 로고
    • Neuropsychiatric involvement in systemic lupus erythematosus: Current therapeutic approach
    • Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr Pharm Des 2008; 14(13): 1261-9.
    • (2008) Curr Pharm Des , vol.14 , Issue.13 , pp. 1261-1269
    • Sanna, G.1    Bertolaccini, M.L.2    Khamashta, M.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.